Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

@article{Collins2008CrystalSO,
  title={Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants},
  author={Patrick J. Collins and Lesley F. Haire and Yi Pu Lin and Junfeng Liu and Rupert J. M. Russell and Philip A Walker and John J. Skehel and Stephen R. Martin and Alan J. Hay and Steven J. Gamblin},
  journal={Nature},
  year={2008},
  volume={453},
  pages={1258-1261}
}
The potential impact of pandemic influenza makes effective measures to limit the spread and morbidity of virus infection a public health priority. Antiviral drugs are seen as essential requirements for control of initial influenza outbreaks caused by a new virus, and in pre-pandemic plans there is a heavy reliance on drug stockpiles. The principal target for these drugs is a virus surface glycoprotein, neuraminidase, which facilitates the release of nascent virus and thus the spread of… 
Exploring the Cause of Oseltamivir Resistance Against Mutant H274Y Neuraminidase by Molecular Simulation Approach
TLDR
It is suggested that wild-type NA could be more indispensable for the oseltamivir binding, as characterized by minimum number of H-bonds, high flexibility and largest binding affinity than mutant- type NA.
The potential impact of neuraminidase inhibitor resistant influenza
TLDR
Neuraminidase inhibitors, oseltamivir in particular, are the drugs of choice against seasonal influenza, zoonotic H5N1 and are stockpiled as the primary mitigating strategy for pandemic influenza containment and control.
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor
TLDR
It is confirmed that replacement of N2 E119 or I222 results in multidrug resistance, and when the replacements occur together, the sensitivity to NA inhibitors (NAI) is reduced severely, and a novel oseltamivir-zanamivIR hybrid inhibitor, MS-257, remains more effective against drug-resistant N2 and is a promising candidate as a next-generation anti-influenza virus drug.
Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors
TLDR
A parallel screening strategy that simultaneously screens wild-type (WT) and MDR NAs and identifies inhibitors matching the subsite characteristics of both NA-binding sites is proposed, and a new inhibitor, Remazol Brilliant Blue R (RB19, an anthraquinone dye), which inhibited WT NA and M DR NA with IC50 values of 3.4 and 4.5 µM, respectively is identified.
Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system
TLDR
It is demonstrated that oseltamivir displays a dose-dependent inhibition on NA activity, and it is believed that as new mutations appear in influenza isolates, their impact on the effectiveness of current and future anti-NA can be quickly and reliably evaluated by this assay.
Oseltamivir Resistance and the H274Y Neuraminidase Mutation in Seasonal, Pandemic and Highly Pathogenic Influenza Viruses
TLDR
There is a need to use the NAI drugs prudently to ensure they remain an effective defence against future seasonal and pandemic influenza viruses, along with careful monitoring of levels of resistance in the circulating viruses combined with the further development of new anti-influenza drugs.
Structural basis for oseltamivir resistance of influenza viruses.
TLDR
Crystal structures of enzyme-drug complexes, together with enzymatic properties, of mutants of H5N1 neuraminidase have provided explanations for high level oseltamivir resistance, and implementation of enhanced NA activity due to a D344N mutation by the H275Y mutation suggests an explanation for the recent emergence and predominance of oselTAMivir-resistant influenza A H1N1 viruses.
Resistance Development to Influenza Virus Sialidase Inhibitors
TLDR
The emergence of influenza viruses resistant to sialidase (neuraminidase, NA) inhibitors (NAIs) upon treatment is observed at low frequencies in adult immunocompetent patients, and does not impact significantly the evolution of influenza syndrome but H1N1 viruses naturally resistant to oseltamivir did emerge and spread in 2007–2008, which compromises the clinical effectiveness of the drug.
In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir
TLDR
The docking analysis reveals that mutation (N294S) significantly affects the binding affinity of oseltamivir with mutant type NA, which throws light on the possible effects of drug-resistant mutations on the large functionally important collective motions in biological systems.
Computational investigation of oseltamivir resistance in influenza A (H5N1) virus
Oseltamivir is the most effective antiviral drug used for the treatment and prevention of influenza A infections. Neuraminidase is the principal target for treating patients with H5N1 infection.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
TLDR
It may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs, according to X-ray crystallography, which shows that these two groups of neuraminidases are structurally distinct.
Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.
TLDR
Hemagglutinin affinity for receptors is an essential feature of influenza virus susceptibility to NA inhibitors, both in cell culture and in humans.
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
TLDR
The sensitivity of neuraminidase variants E119G and R292K to BCX-1812 has been measured and found in both cases to be intermediate between those of zanamivir and oseltamivIR.
Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071
TLDR
Results suggest that although the R292K neuraminidase mutation confers high-level resistance to GS 4071 in vitro, its effect on viral virulence is likely to render this mutation of limited clinical significance.
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
TLDR
Both mutant viruses were transmitted, although the H274Y mutant required a 100-fold-higher dose for infection of donor ferrets and was transmitted more slowly than was the wild type.
Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility
TLDR
The results suggest that NAI-resistant influenza virus variants may differ substantially in fitness and transmissibility, depending on different levels of NA functional loss.
Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir
TLDR
The data indicate that genetic variation in the absence of any drug-selective pressure may result in significant variations in sensitivity to anti-NA drugs, and underscores the need for continuous evaluation of the impact of genetic drift on this parameter, especially for influenza viruses with pandemic potential.
Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase.
TLDR
Results provide evidence that a general strategy for drug design when the target has a high mutation frequency is to design the inhibitor to be as closely related as possible to the natural ligands of the target.
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
TLDR
Virus carrying H274Y NA enzyme selected in vivo has reduced sensitivity to oseltamivir carboxylate, and pathogenicity of the mutant virus is significantly compromised in ferret, compared to the corresponding wild type virus.
Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo
TLDR
The results suggest that NA inhibitor-resistant H5N1 variants may retain the high pathogenicity of the wild-type virus in mammalian species and patients receiving NA inhibitors for H1N1 influenza virus infection should be closely monitored for the emergence of resistant variants.
...
1
2
3
4
...